Adolescents with radiologically confirmed substantial congenital midline defects affecting the hypothalamic-pituitary region, such as pituitary stalk interruption syndrome (PSIS) or septo-optic dysplasia (SOD) should continue GH therapy if they present with an additional deficiency of ≥ 2 other pituitary hormones. This evidence concerns the gene GH1 and pituitary stalk interruption syndrome.